|
MechanismEPO receptor agonists |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.India |
First Approval Date01 Jan 2012 |
A Phase-III, Randomized, Open Label, Parallel Group, Active Controlled, Multicentre, Non-Inferiority Clinical Study to Evaluate the Immunogenicity and Safety Of Varivax® [Varicella vaccine (Live Attenuated, Lyophilized I.P) of VHB Life Sciences Limited] Compared to a Marketed Varicella Vaccine in Healthy Paediatric Subjects aged between 1 to 12 years.
100 Clinical Results associated with VHB Life Sciences Ltd.
0 Patents (Medical) associated with VHB Life Sciences Ltd.
100 Deals associated with VHB Life Sciences Ltd.
100 Translational Medicine associated with VHB Life Sciences Ltd.